Clear All
11564 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
71288-0116-11 71288-0116 Busulfan Busulfan 6.0 mg/mL Chemotherapy Alkylating Agent Alkylsulfonate Intravenous Oct 23, 2020 In Use
80725-0620-25 80725-0620 Busulfan MYLERAN 2.0 mg/1 Chemotherapy Alkylating Agent Alkylsulfonate Oral May 15, 2023 In Use
59148-0047-91 59148-0047 Busulfan Busulfex 6.0 mg/mL Chemotherapy Alkylating Agent Alkylsulfonate Intravenous Feb 13, 2015 Jan 31, 2021 No Longer Used
00517-0920-08 00517-0920 Busulfan Busulfan 6.0 mg/mL Chemotherapy Alkylating Agent Alkylsulfonate Intravenous Apr 1, 2017 In Use
69784-0620-25 69784-0620 Busulfan MYLERAN 2.0 mg/1 Chemotherapy Alkylating Agent Alkylsulfonate Oral Jun 30, 2022 In Use
14789-0013-10 14789-0013 Busulfan Busulfan 60.0 mg/10mL Chemotherapy Alkylating Agent Alkylsulfonate Intravenous Sep 15, 2023 Jul 21, 2024 No Longer Used
55150-0395-08 55150-0395 Busulfan Busulfan 6.0 mg/mL Chemotherapy Alkylating Agent Alkylsulfonate Intravenous Jun 25, 2024 In Use
65219-0160-10 65219-0160 Busulfan Busulfan 6.0 mg/mL Chemotherapy Alkylating Agent Alkylsulfonate Intravenous Nov 11, 2019 In Use
76189-0113-18 76189-0113 Brigatinib Alunbrig 30.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK/ROS1/ EGFR Oral Apr 28, 2017 Dec 12, 2020 No Longer Used
76189-0113-21 76189-0113 Brigatinib Alunbrig 30.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK/ROS1/ EGFR Oral Apr 28, 2017 Dec 12, 2020 No Longer Used
71287-0219-02 71287-0219 brexucabtagene autoleucel TECARTUS 2000000.0 1/68mL Immunotherapy CAR-T CD19 Intravenous Jul 24, 2020 In Use
71287-0220-02 71287-0220 brexucabtagene autoleucel TECARTUS 1000000.0 1/68mL Immunotherapy CAR-T CD19 Intravenous Oct 1, 2021 In Use
51144-0050-01 51144-0050 Brentuximab vedotin Adcetris 50.0 mg/10.5mL Immunotherapy Drug Antibody Conjugate CD30 Intravenous Aug 25, 2011 In Use
00069-0504-30 00069-0504 Bosutinib BOSULIF 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan 2, 2024 In Use
00069-1014-15 00069-1014 Bosutinib BOSULIF 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan 2, 2024 In Use
00069-0193-01 00069-0193 Bosutinib monohydrate, Bosutinib BOSULIF 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Dec 18, 2017 In Use
00069-0136-01 00069-0136 Bosutinib monohydrate, Bosutinib Bosulif 500.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 4, 2012 In Use
63539-0117-01 63539-0117 Bosutinib monohydrate, Bosutinib Bosulif 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 4, 2012 In Use
00069-0135-01 00069-0135 Bosutinib monohydrate, Bosutinib Bosulif 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 4, 2012 In Use
00143-9098-01 00143-9098 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous Jul 27, 2022 In Use
68001-0540-36 68001-0540 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 16, 2022 In Use
72603-0270-01 72603-0270 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous Nov 1, 2024 In Use
55150-0337-01 55150-0337 BORTEZOMIB BORTEZOMIB 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 In Use
00409-1704-01 00409-1704 BORTEZOMIB BORTEZOMIB 1.0 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 16, 2022 In Use
72338-0200-01 72338-0200 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous Jun 19, 2018 In Use

Found 11564 results — Export these results